Net product sales consist of the following: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
June 30, | | Six Months Ended June 30, | | (In millions) | | | | 2025 | | 2024 | | 2025 | | 2024 | EYLEA HD® | | U.S. | | $ | 393.2 | | | $ | 304.2 | | | $ | 700.0 | | | $ | 504.2 | | EYLEA® | | U.S. | | 754.3 | | | 1,230.5 | | | 1,490.3 | | | 2,432.1 | | | Total EYLEA HD and EYLEA | | U.S. | | 1,147.5 | | | 1,534.7 | | | 2,190.3 | | | 2,936.3 | | Libtayo® | | U.S. | | 247.8 | | | 182.4 | | | 440.3 | | | 341.6 | | Libtayo | | Rest of world | | 128.7 | | | 115.0 | | | 221.3 | | | 219.7 | | Total Libtayo | | Global | | 376.5 | | | 297.4 | | | 661.6 | | | 561.3 | | Praluent® | | U.S. | | 65.8 | | | 56.1 | | | 122.6 | | | 126.1 | | Evkeeza® | | U.S. | | 41.2 | | | 30.4 | | | 72.1 | | | 55.2 | | Inmazeb® | | Rest of world | | — | | | — | | | — | | | 1.0 | | | | | | $ | 1,631.0 | | | $ | 1,918.6 | | | $ | 3,046.6 | | | $ | 3,679.9 | |
Amounts recognized in the Company's Statements of Operations in connection with its Sanofi collaboration are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Statement of Operations Classification | | Three Months Ended June 30, | | Six Months Ended June 30, | | (In millions) | | | 2025 | | 2024 | | 2025 | | 2024 | Regeneron's share of profits | | Collaboration revenue | | $ | 1,282.1 | | | $ | 988.3 | | | $ | 2,300.2 | | | $ | 1,792.3 | | | Reimbursement for manufacturing of commercial supplies | | Collaboration revenue | | $ | 161.5 | | | $ | 157.3 | | | $ | 326.6 | | | $ | 263.1 | | | Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses | | R&D expense | | $ | (18.0) | | | $ | (9.1) | | | $ | (33.5) | | | $ | (27.7) | | Reimbursement of commercialization-related expenses | | Reduction of SG&A expense | | $ | 194.0 | | | $ | 150.8 | | | $ | 353.2 | | | $ | 290.3 | |
Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Statement of Operations Classification | | Three Months Ended June 30, | | Six Months Ended June 30, | | (In millions) | | | 2025 | | 2024 | | 2025 | | 2024 | Regeneron's share of profits | | Collaboration revenue | | $ | 383.4 | | | $ | 353.0 | | | $ | 700.7 | | | $ | 686.9 | | Reimbursement for manufacturing of commercial supplies | | Collaboration revenue | | $ | 31.6 | | | $ | 22.1 | | | $ | 58.2 | | | $ | 44.2 | | | Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses | | R&D expense | | $ | (5.6) | | | $ | (14.7) | | | $ | (15.0) | | | $ | (23.4) | |
|